DONEPEZIL V LEChENII BOLEZNI AL'TsGEYMERA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This report considers the clinical efficacy and safety of one of the leading drug for the correction of central cholinergic deficits in patients with Alzheimer's disease (AD), donepezil (Alzepil, Egis, Hungary), which past two years was used in Russia. Donepezil has shown effectiveness in both cognitive and behavioral correction of disorders in AD patients. Furthermore, donepezil may be included in the scheme of therapy in AD patients with moderate and even severe dementia.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Kolykhalov

Email: ikolykhabv@yandex.ru

Әдебиет тізімі

  1. Ferri C, Prince V Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-17.
  2. Davies P Maloney AJF Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403-404.
  3. Schneider LS. New therapeutic approaches to Alzheimer's disease J Clin Psychiatry 1996;57(Suppl. 14):30-6.
  4. Delrieu J, Piau A, Caillaud C, et al. Managing cognitive dysfunction through the continuum of Alzheimer's disease. Role of pharmacotherapy. CNS Drugs 2011;25:213-26.
  5. Руководство по гериатрической психиатрии / Под ред. С.И. Гавриловой. М., 2011. 380 с.
  6. Forette F, Boller F. Drug development in Alzheimer's Disease In: Gauthier S.(ed). London: Martin Dunitz, 1988:1-15.
  7. Гаврилова С.И., Жариков Г.А. Современные стратегии патогенетической терапии болезни Альцгеймера. // Вестник РАМН 2001. № 7. С. 13-8.
  8. Yamanishi Y, Ogura H, Kosasa T, et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T., Fisher A., Yoshida M. (eds.): Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. New York: Plenum Press, 1990;2: 409-13.
  9. Rogers SL, Friedhoff LT, and Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7: 293-303.
  10. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105.
  11. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003:CD001190.
  12. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489.
  13. Rockwood K, Graham J, Fay S. Goal setting and attainment in patients with Alzheimer's disease treated with donepezil. J Neurol, Neurosurgery, Psychiatry 2002;3:500-07.
  14. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481.
  15. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427.
  16. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136.
  17. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc 2009;57:1997.
  18. Mesulam M. The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show? Learn Mem 2004;11:43-9.
  19. Pappas BA, Bayley PJ, Bui BK, et al. Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol Aging. 2000;21:11-7.
  20. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-99.
  21. Shinotoh H, Aotsuka A, Fukushi K, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001;56:408-10.
  22. Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002; 22:615-20.
  23. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010;32:1234.
  24. Barak Y, Bodner E, Zemishlani H, et. al. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr 2001;33:237-41.
  25. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:134-40.
  26. Clary C, McRae T, Griesing T, et al. The safety of donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease (abstract). Int J Neuropsyhopharmacol 2000;3(Suppl. l):267.
  27. Жариков Г.А., Калын Я.Б., Колыхалов И.В. и др. Опыт применения арисепта (донепези-ла) в лечении болезни Альцгеймера. В кн. Болезнь Альцгеймера и старение. Материалы III Российской конференции / Под ред. С.И. Гавриловой. М., 2003. С. 76-87.
  28. Карпюк В.А., Дудук С.Л., Лелявко И.А., и др. Изучение эффективности и безопасности Алзепила (донепезила) для лечения болезни Альцгеймера на стадии мягкой и умеренно выраженной деменцией // Современная терапия в психиатрии и неврологии 2012. № 3. С. 27-32.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>